Mutational analysis of conserved aromatic residues in the A-loop of the ABC transporter ABCB1A (mouse Mdr3)  by Carrier, Isabelle et al.
FEBS Letters 581 (2007) 301–308Mutational analysis of conserved aromatic residues in the A-loop
of the ABC transporter ABCB1A (mouse Mdr3)
Isabelle Carriera, Ina L. Urbatscha,b,1, Alan E. Seniorb, Philippe Grosa,*
a Department of Biochemistry and McGill Cancer Centre, McGill University, McIntyre Medical Sciences Building, Room 907,
3655 Sir William Osler Drive, Montre´al, Que., Canada H3G 1Y6
b Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY 14642, United States
Received 20 November 2006; accepted 15 December 2006
Available online 3 January 2007
Edited by Ulf-Ingo Flu¨ggeAbstract The A-loop is a recently described conserved region in
the NBDs of ABC transporters [Ambudkar, S.V., Kim, I.-W.,
Xia, D. and Sauna, Z.E. (2006) The A-loop, a novel conserved
aromatic acid subdomain upstream of the Walker A motif in
ABC transporters, is critical for ATP binding. FEBS Lett.
580, 1049–1055; Kim, I.W., Peng, X.H., Sauna, Z.E., FitzGer-
ald, P.C., Xia, D., Muller, M., Nandigama, K. and Ambudkar,
S.V. (2006) The conserved tyrosine residues 401 and 1044 in
ATP sites of human P-glycoprotein are critical for ATP binding
and hydrolysis: evidence for a conserved subdomain, the A-loop
in the ATP-binding cassette. Biochemistry 45, 7605–7616]. In
mouse P-glycoprotein (Abcb1a), the aromatic residue of the A-
loop in both NBDs is a tyrosine: Y397 in NBD1 and Y1040 in
NBD2. Another tyrosine residue (618 in NBD1 and 1263 in
NBD2) also appears to lie in proximity to the ATP molecule.
We have mutated residues Y397, Y618, Y1040, and Y1263 to
tryptophan and analyzed the eﬀect of these substitutions on
transport properties, ATP binding, and ATP hydrolysis by
Abcb1a (mouse Mdr3). Y618W and Y1263W enzymes had cata-
lytic characteristics similar to WT Abcb1a. On the other hand,
Y397W and Y1040W showed impaired transport and greatly
reduced ATPase activity, including a 10-fold increase in Km
for MgATP. Thus, Y397 and Y1040 play an important role in
Abcb1a catalysis.
 2006 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
Keywords: ABC transporter; ATP hydrolysis; Abcb1a;
Nucleotide-binding domain; Site-directed mutagenesisAbbreviations: 3-D, three-dimensional; ABC, ATP-binding cassette;
Abcb1a, mouse P-glycoprotein/Mdr3/Mdr1a; COL, colchicine; DTT,
dithiothreitol; E. coli, Escherichia coli; MDR, multidrug resistance;
NBD, nucleotide-binding domain; NBD1, N-terminal nucleotide-
binding site; NBD2, C-terminal nucleotide-binding site; Pgp, P-glyco-
protein; Pi, inorganic phosphate; SDS–PAGE, sodium dodecyl
sulphate–polyacrylamide gel electrophoresis; TMD, trans-membrane
domain; TPP+, tetraphenylphosphonium bromide; VAL, valinomycin;
VBL, vinblastine; VER, verapamil; Vi, ortho-vanadate ðVO4 Þ; WT,
wild-type
*Corresponding author. Fax: +1 514 398 2603.
E-mail address: philippe.gros@mcgill.ca (P. Gros).
1Present address: Department of Cell Biology and Biochemistry,
Texas Tech University Health Sciences Center, Lubbock, TX 79430,
United States.
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.12.0301. Introduction
Members of the ATP-binding cassette (ABC) family of
membrane transporters use ATP hydrolysis to transport a
variety of structurally dissimilar substrates including ions, pep-
tides, lipids, nucleotides, and chemotherapeutic drugs, across
the phospholipid bilayer [3,4]. Mutations in almost half of
the 48 human ABC transporters have severe patho-physiolog-
ical eﬀects and cause diseases in humans [4].
The deﬁning features of this family include two membrane-
spanning domains (TMDs), usually consisting of six trans-
membrane a-helices in each, and two cytoplasmic nucleotide-
binding domains (NBDs) [5,6]. While the TMDs are involved
in substrate binding and transport, the NBDs bind and hydro-
lyze ATP and energize transport [7,8]. The NBDs contain
a number of conserved sequence motifs: the Walker A
(GXSGCGKST) and B (ILLLDEA) motifs, the signature re-
gion (LSGGQ), and the A, D, H, and Q structural loops [9].
These highly conserved subdomains cluster around the bound
nucleotide(s) and play important roles in positioning MgATP
(Walker A and B motifs, signature region, and the A and
H-loops), in the activation of the catalytic water molecule
(extended Walker B, H-loop), and in the signal transduction
between the NBDs, and the NBDs and TMDs (D and Q
loops).
ABCB1, also known as P-glycoprotein/MDR1, functions as
a ﬂippase for phospholipids in normal cells, but can also act on
xenobiotics, such as anti-cancer drugs, when it is inserted in the
lipid bi-layer. It has been established that (1) drug transport is
strictly ATP dependent [10,11], (2) puriﬁed Pgp shows ATPase
activity that can be further stimulated by certain MDR drugs
and Pgp modulators [12,13], (3) both NBDs are essential for
function, with complete cooperativity between the two sites
for ATP hydrolysis and drug transport [14–16], (4) both NBDs
are catalytically active with equal probability of hydrolysis at
NBD1 and NBD2 [7], and (5) ATP hydrolysis alternates
between the two sites [7,17]. Other mechanistic aspects of
Pgp function are not fully understood.
The increasing availability of high resolution three-dimen-
sional (3-D) crystal structures has provided a structural frame-
work to understand the function and mechanism of action of
many proteins. For example, 3-D crystal structures for several
ABC transporters and ABC-like proteins (HisP, Rad50,
MalK, MJ0796, MJ1267, TAP1, MsbA, BtuCD, GlcV, HlyB,
and CFTR) [18–31], in particular those with bound nucleotide,
have helped to establish the fact that the NBDs form a dimer
that sandwiches nucleotide(s) between the Walker A and Bblished by Elsevier B.V. All rights reserved.
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other [32]. In addition, they have helped in the identiﬁcation of
the residues that appear to be critical for catalysis [30,33]; as
well as exposed the role of the aromatic amino acid 25 resi-
dues upstream of the Walker A motif. Although previous ﬁnd-
ings by several groups [34–37] had hinted at the role for this
conserved aromatic residue, the 3-D structures have now con-
ﬁrmed its strategic location with respect to bound nucleotide
(Fig. 1). Indeed, as Ambudkar and colleagues have demon-
strated, this residue contributes to the positioning of ATP in
the active site of Pgp/ABCB1 via p–p interactions with the ade-
nine ring of ATP [1,2]. This is also the case for the MRP1 and
HlyB proteins [36,37]. Although most of the binding energy for
ATP appears to be contributed by the phosphate groups [38],
the nucleotide speciﬁcity and further stabilization of nucleotide
binding may be contributed by residues which interact with the
nucleoside moiety. A recent large-scale data-mining study of
ATP-bound crystal structures (including some members of
the ABC-transporter family) by Mao et al., determined that
the molecular determinants for recognition of the adenine moi-
ety of ATP by proteins includes hydrogen bonding, Van der
Waals, p–p stacking, and cation-p stacking interactions, of
which aromatic residues are good candidates for p–p stacking
[39].
An important but poorly understood aspect of catalysis by
ABC transporters is the nucleotide occupancy of the two active
sites during a full cycle of ATP hydrolysis. We wanted to inves-
tigate the NBD residues that were labeled by photoactive
nucleotide analogs during the catalytic cycle of Pgp. These res-
idues were labeled (a) in the presence of the transition state
analog vanadate (Vi), which traps ADP in the site undergoing
catalysis, and (b) in the absence of Vi to mimic the ATP-bound
structure of the NBD. Under Vi trapping conditions, residues
Y398 and Y1041 in NBD1 and NBD2 of hamster Pgp, respec-
tively, were found to be covalently modiﬁed by 8-azido-
[a-32P]ATP [35]. Fig. 1 shows the position of these residues
in the NBD as modeled by HisP. Under binding conditions
(absence of Vi) Y619 in NBD1 was covalently labeled by 8-azi-
do-[a-32P]ATP (unpublished results2). The equivalent tyrosine
residue in NBD2 is Y1264 and was not found to be labeled in
these experiments. Y619 and Y1264 are located near the C-ter-
minal of both NBDs, following all conserved motifs. In the
crystal structure of HisP, the equivalent position is located in
the last alpha helix, which is about 18 A˚ away from the ade-
nine moiety in the crystal structure (Fig. 1). These photo-label-
ing studies suggest that at least three aromatic residues,
including those of the A-loop, are in the proximity of the
ATP nucleotide during binding and hydrolysis. To further
characterize the functional role of these four aromatic residues,
we have replaced each residue in mouse P-glycoprotein (Abc-
b1a/Mdr3) by the bulkier aromatic residue tryptophan and
studied the eﬀect of these changes on transport function,
ATP binding, and ATP hydrolysis by Pgp.2Essentially same methodology as in [35] but omitting Vi. Plasma
membranes were incubated at 1 mg/mL protein with 50 lM 8-azido-
[a-32P]ATP in 40 mM Tris–HCl, pH 7.4, 0.1 mM EGTA, 2 mM
MgSO4, and 10 lM verapamil at 0 C. Samples were subjected to UV-
photolysis, and then precipitated by TCA. The protein was then
digested with trypsin and radiolabelled peptides were separated by
Al-chelate aﬃnity chromatography. The radiolabelled peptides were
then separated by HPLC on a C18 column. The sequence of the major
radioactive peak produced Y619 as being covalently modiﬁed.2. Materials and methods
2.1. Abcb1a cDNA modiﬁcations and plasmid constructions
Mutants Y397W and Y1040W were constructed by site-directed
mutagenesis using a recombinant PCR approach as described
previously [40]. To create the Y397W mutation in NBD1, the
5 0-CGATGGCCAACTGAAGTGAATATTC-3 0 mutagenic oligo
containing the NruI site was used with the primer TK-5 (5 0-
GTGCTCATAGTTGCCTACA-3 0) on ssHL6 template DNA (Abcb1a
with ﬁrst six tryptophans replaced by phenylalanine). The 553 bp
MscI–NruI fragment carrying the mutated segment was puriﬁed
and used to replace the corresponding fragment in the pVT-mdr3
construct [41]. For the homologous mutation Y1040W in NBD2, two
overlapping fragments were synthesized using two pairs of primers:
pair 1, 5 0-GTGTTCAACTGGCCCACCCG-3 0 forward mutagenic
oligo and primer HincII (5 0-AGAAAGCTGTTAACGAAGCC-3 0);
pair 2, 5 0-CGGGTGGGCCAGTTGAACAC-3 0 reverse mutagenic
oligo and primer MfeI (5 0-CACACTGACAATTGAGAAG-3 0).
The overlapping fragments containing the inserted mutations
were annealed, followed by a second PCR ampliﬁcation using
primers HincII and MfeI. The 319 bp SpeI–XhoI fragment
carrying the mutated segment was puriﬁed and used to replace the
corresponding fragment in the full length Abcb1a cDNA contained
in the yeast expression construct pVT-mdr3.5 [16]. To create the
Y618W mutation in NBD1, a 2.2 kb EcoRI fragment of Abcb1a (posi-
tions 93–2248) was cloned in the corresponding site of phage vector
M13mp18 [16], and single-stranded DNA was used as a template for
site-directed mutagenesis using a commercially available kit (Amer-
sham, Arlington Heights, IL), and the mutagenic oligonucleotide
(5 0)-CATGACAAGTTTAAACCAAATGCCCTTTT-(3 0). For the
homologous NBD2 mutation Y1263W, a PstI–HindIII abcb1a frag-
ment (positions 3511–4199) from pDR16 was inserted in the corre-
sponding sites of M13mp18, with a SnaBI site introduced after the
last amino acid (3889) [16]. The Y1263W mutation was introduced
using the mutagenic oligo (5 0)-GACCATTGAGAACCAAATGCC-
CTTCTG-(3 0). The nucleotide sequence of the mutated segments
was veriﬁed prior to their insertion in the corresponding sites of
pVT-mdr3 (NBD1 mutation, using EcoRI and MscI) or pVT-mdr3.5
(NBD2 mutation, using PstI and SnaBI). pVT vectors containing
either WT or mutant DNA were then transformed into Saccharomyces
cerevisiae for biological testing, as previously described [42,43].
2.2. Testing of Abcb1a function in yeast cells
pVT-mdr3 plasmids carrying either wild-type (WT) or mutant ver-
sions of Abcb1a were transformed in the yeast S. cerevisiae strain
JPY201 (MATaste6Dura3) using a lithium acetate technique [44].
The biological activity of mass populations of yeast cells transformed
with individual plasmids was tested with respect to their capacity to
convey cellular resistance to the anti-fungal agent FK506 (50 lg/mL)
and to restore mating in the ste6D sterile yeast as previously described
[42,43]. Expression of WT and mutant Abcb1a proteins was monitored
by immunoblotting using the monoclonal anti-Pgp antibody C219
(Signet Labs Inc.).
2.3. Plasmid constructions and transformation into Pichia pastoris
NBD1 mutants were excised from pVT-mdr3 as AﬂII–EcoRI frag-
ments and NBD2 mutants were excised from pVT-mdr3.5 as AﬂII–
SnaBI fragments, and substituted in the Pichia pastoris expression
vector pHIL-mdr3.5-His6. pHIL-mdr3.5-His6 carrying either WT or
mutant versions of Abcb1a, as well as the control pHIL-D2 vector,
were transformed into Pichia pastoris strain GS115 according to the
manufacturer instructions (In Vitrogen, license number 145457).
His+ transformants showing successful homologous recombination
at the AOX1 locus were identiﬁed as unable to grow on medium
containing methanol (methanol utilizing slow, muts), as previously
described [45].2.4. Membrane preparations
P. pastoris clones were picked and transferred to 10 mL cultures
followed by a 72 h induction of AOX1 with methanol, as previously
described [16]. Cells were then collected and lysed to obtain crude plas-
ma membranes, as previously described [16]. Abcb1a expression was
monitored by immunoblotting with the anti-Pgp monoclonal antibody
C219. For large-scale preparations of P. pastoris membranes, cultures
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Fig. 1. Positioning and conservation of tyrosine residues in the NBDs of Pgp. (A) Crystal structure of HisP, the NBD of Histidine permease from S.
typhimurium, showing the position of ATP, as determined by Hung et al. [18]. The protein is shown as a ribbon model and ATP as a ball-and-stick
model. (B) Atomic details of the interactions of residues surrounding the ATP molecule in HisP; the equivalent residues in NBD1 and NBD2 of
Abcb1a are shown. Modiﬁed from [18]. (C,D) Sequence alignment of HisP with mouse Abcb1a and human MDR1 NBD1 (C) and NBD2 (D). Dots
indicate gaps that were introduced to optimize alignment. The numbers below the tyrosine residue thought to interact with the adenine ring of ATP
represent the number of sequences of other NBDs where a Y (or any aromatic residue: Y, F, or W) is also present at that position, over the total
number of sequences aligned at that position.
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branes were isolated either by centrifugation on discontinuous sucrose
density gradients [45] or by a modiﬁed protocol [46]. From a 1 L cul-
ture we routinely obtained about 50 mg of total membrane protein and
350 lg of pure Pgp.
2.5. Solubilization and puriﬁcation of Abcb1a
To obtain pure protein, 30 mg of P. pastoris membranes (1–2 mg/
mL) were used in a protocol previously described [16], except that
1 mL of packed Ni-NTA resin (Qiagen), 100 mL of buﬀer A, 20 mL
of buﬀer B and 3 · 1 mL of buﬀer C were employed. Also, Abcb1a
was further eluted using 2 · 1.5 mL of buﬀer D (50 mM Tris–HCl,
pH 8.0, 20% glycerol, 150 mM imidazole, 0.1% DM). For reconstitu-
tion of Abcb1a, the 80 and 150 mM imidazole eluates were incubated
with 0.3% E. coli lipids (w/v) (Avanti, acetone/ether preparation) for
30 min on ice, followed by dialysis against 1 L dialysis buﬀer
(50 mM Tris–HCl, pH 7.4, 0.1 mM EGTA, and 1 mM DTT). Abcb1a
proteoliposomes were recuperated by centrifugation (100000 · g,
30 min), resuspended in dialysis buﬀer, aliquoted and stored at
80 C until use. For the 8-azido-nucleotide trapping experiments,
the protein was puriﬁed according to a more recent protocol where cul-
tures were induced with 1% methanol for 72 h and plasma membranes
isolated by centrifugation, as previously described in [46]. Solubiliza-
tion and puriﬁcation of WT and mutant Abcb1a variants by aﬃnity
chromatography on Ni-NTA resin (Qiagen) and DE52-cellulose
(Whatman) was as described in [46].2.6. Assay of ATPase activity
Reactions were carried out in 50 lL of 50 mM Tris–HCl, pH 8.0,
0.1 mM EGTA, 10 mM Na2ATP, and 10 mM MgCl2 at 37 C for
appropriate times during which the reaction was linear, and 610%
of added nucleotide was hydrolyzed. Reactions were initiated by
addition of puriﬁed reconstituted Abcb1a, and stopped by addition
of 1 mL of 20 mM ice-cold H2SO4. Pi release was assayed by the
method of Van Veldhoven and Mannaerts [47]. For determination
of kinetic parameters, an excess of 2 mM MgCl2 over MgATP
concentrations was used. Drugs were added as dimethyl sulfoxide
solutions, and the ﬁnal solvent concentration in the assay was kept
at 62% (v/v).2.7. Photo-aﬃnity labeling with 8-azido-[a-32P]ATP
8-Azido-[a-32P]ATP photo-aﬃnity labeling was performed essen-
tially as previously described [48] with minor modiﬁcations: FK506
was added to a ﬁnal concentration of 30 lM where indicated.2.8. Materials
8-Azido-[a32P]ATP (8.5 Ci/mmol) was purchased from ICN or
Aﬃnity Labeling Technologies, Inc. Verapamil was purchased from
ICN. Valinomycin and FK 506 were purchased from Calbiochem.
Acetone/ether-precipitated E. coli lipids were from Avanti Polar
Lipids. General chemicals were of reagent grade from Sigma.
Fig. 2. Eﬀect of Y397W, Y618W, Y1040W and Y1263W mutations on
Abcb1a-mediated resistance to FK506 in S. cerevisiae cells. The
capacity of WT and mutant Abcb1a variants to confer cellular
resistance to FK506 in the yeast S. cerevisiae was measured using a
growth inhibition assay in liquid medium. (A) Growth of individual
mass populations of transformants was measured over time in drug-
free medium. (B) Growth of the same individual mass populations in
medium containing FK506 at 50 lg/mL; relative growth is expressed as
percent of growth in FK506-containing vs drug-free medium. The pVT
negative control does not express Abcb1a. Shown is one representative
of three independent experiments.
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3.1. Expression and characterization of Y397W, Y618W,
Y1040W and Y1263W Abcb1a mutants in S. cerevisiae
We have previously shown that expression of mouse Pgp
(Abcb1a) in the yeast S. cerevisiae confers resistance to the
antifungal macrolides FK506 and FK520 [43], and comple-
ments the biological activity of the a factor pheromone
ABC transporter STE6, restoring mating in an otherwise
sterile yeast ste6D mutant [42]. Mutants Y397W, Y618W,
Y1040W and Y1263W were transformed in S. cerevisiae strain
JPY201. Immunoblotting of crude membrane fractions from
yeast transformants, using the anti-Pgp antibody C219,
showed similar levels of expression of the various mutants,
comparable to WT (data not shown), suggesting that the
mutations do not have a major eﬀect on protein expression,
stability or membrane targeting in yeast.
The ability of these mutants to confer resistance to the
fungicide and Pgp substrate FK506 was tested in a growth
inhibition assay in liquid medium (Fig. 2). In drug-free
medium, all transformants showed identical growth proﬁles
(Fig. 2A). The growth rate of each transformant population
in FK506 was expressed as the percentage of growth in the
presence of drug compared to growth in the absence of drug
(Fig. 2B). While mutants Y618W and Y1263W showed
growth rates similar to those measured in WT-expressing cells
(>85% growth of WT at 24 h), mutant Y1040W showed a
reduced growth phenotype (30% of WT at 24 h) and mutant
Y397W was severely impaired for growth in FK506 (<10% of
WT at 24 h). The ability of the Y397W, Y618W, Y1040W
and Y1263W mutants to restore mating in the sterile ste6D
yeast strain JPY201 was also tested (Fig. 3). The behavior
of the four mutants in the mating assay (Fig. 3) paralleled
that observed in the growth inhibition assay with FK506:
mutants Y397W and Y1040W were functionally impaired
while mutants Y618W and Y1263W behaved as WT Abcb1a.
Thus, introduction of tryptophan residues at positions Y618
and Y1263 do not appear to aﬀect enzyme activity, whereas
introduction at positions Y397 and Y1040 appear to have a
signiﬁcant eﬀect on enzyme activity, implying that the latter
two residues are important for enzyme function. Moreover,
the similar results obtained for the equivalent mutations in
the two NBDs suggest that these residues play similar roles
in both NBDs.
3.2. Characterization of the ATPase activity of Y397W,
Y618W, Y1040W and Y1263W Abcb1a mutants expressed
in P. pastoris
The eﬀect of the Y397W, Y618W, Y1040W and Y1263W
mutations on Abcb1a ATPase activity was measured following
expression and puriﬁcation ofWT and mutant Abcb1a variants
from P. pastorismembranes and reconstitution in E. coli lipids.
ATPase activity was measured in the absence or presence of
several Pgp substrates, including verapamil (VER), valinomy-
cin (VAL), vinblastine (VBL), colchicine (COL), tetraphenyl-
phosphonium bromide (TPP+), and FK506 [45,49]. Although
the stimulation proﬁles for the four tryptophan mutants were
qualitatively similar to WT (Fig. 4); mutants Y618W and
Y1263W showed maximal levels of drug-stimulated ATP
hydrolysis similar to WT, while mutants Y397W and
Y1040W showed a signiﬁcant reduction in maximal stimula-
tion. This loss of activity could thus account for the signiﬁcantimpairment of biological activity in S. cerevisiae, as a certain
level of ATPase activity is necessary to maintain drug/phero-
mone transport [33].
The ATPase activity of the four mutants was also evaluated
in increasing amounts of ATP. Puriﬁed reconstituted Abcb1a
showed a single high Km for MgATP hydrolysis (Fig. 5A)
which was similar in the absence (0.2 mM) or presence of
verapamil (0.5 mM), valinomycin (0.4 mM), or FK506
(0.5 mM). The Km values for drug-stimulated ATP hydrolysis
measured in the mutants Y618W and Y1263W were very sim-
ilar to those obtained with WT Abcb1a (data not shown).
However, Km for drug-stimulated ATP hydrolysis was much
higher (Km ATP 1.5–9 mM) in the Y397W and Y1040W
mutants (Fig. 5B and C). Such high Km values have not been
previously described for any other point mutations in
Abcb1a, but also suggest that these two tyrosine residues
Fig. 3. Eﬀect of Y397W, Y618W, Y1040W and Y1263Wmutations on
Abcb1a-mediated mating in S. cerevisiae cells. Patches of JPY201 cells
transformed with either pVT-Mdr3, pVT-Y397W, pVT-Y1040W,
pVT-Y618W, pVT-Y1263W, pVT-STE6 (positive control), or pVT-
DEN (negative control) were mated to a lawn of DC17 tester stock
(MATahis1). Mating was allowed to proceed for 12 h at 30 C before
transfer onto minimal plates to assess diploid formation. Shown is one
representative of two independent experiments.
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acts with the adenine moiety of ATP (Fig. 1), with Y401 and
Y1044 in NBD1 and NBD2, respectively, of ABCB1, with
W653 and Y1302 in NBD1 and NBD2, respectively, of
MRP1, and with Y477 of HlyB. Indeed, mutation of Y16
to serine in HisP actually abolished ATP binding and trans-
port activity (because the ATPase domain is a homodimer,
only the double mutant was studied) [34]. Mutation of the
equivalent residues in ABCB1, MRP1 and HlyB also caused
an increase in Km [1,36,37]. Our results conﬁrm that Y397
and Y1040 play an important role in ATP binding and/or
hydrolysis by Pgp.Fig. 4. ATPase activity of puriﬁed reconstituted Y397W, Y618W, Y1040W
were assayed as described in Section 2. All values are the means of at le
vinblastine (VBL), colchicine (COL), FK506, and tetraphenylphosphonium b
and 50 lM, respectively.3.3. Photolabeling with Mg-8-azido-[a-32P]-ATP
The altered Km values for ATP hydrolysis detected in
Y397W and Y1040W suggested alterations in nucleotide bind-
ing and/or hydrolysis in these mutants. The nucleotide-binding
properties of the four mutants were monitored by photo-aﬃn-
ity labeling with the nucleotide analogue 8-azido-[a-32P]ATP
[48]. For this, puriﬁed mutants were exposed to increasing
amounts of 8-azido-[a-32P]ATP, followed by cross-linking with
UV, separation by SDS–PAGE and autoradiography. Results
in Fig. 6A suggest that none of the mutations had a major
deleterious eﬀect on the overall ATP binding properties of
the protein.
Vi-induced trapping of 8-azido-[a32P]ADP under hydrolysis
conditions (37 C) has been used as an alternative and highly
sensitive method to monitor ATPase activity in WT and mu-
tant Pgp [16]. Fig. 6B demonstrates that Y618W and
Y1263W trap 8-azido-ADP at levels comparable to WT,
whereas trapping by the mutants Y397W and Y1040W is
greatly reduced (faint bands observed for Y397W and
Y1040W in the presence of verapamil and vanadate upon over-
exposure of ﬁlm, not shown). The reduction in labeling of the
Y397W and Y1040W mutants is consistent with a lower rate of
ATP hydrolysis (Fig. 4), and with the eﬀect of the mutations
on Km for the nucleotide substrate (Fig. 5B and C). In fact,
the 8-azido-[a32P]ATP concentration used (5 lM) in the trap-
ping experiments is well below the Km value for 8-azido-ATP
(400–600 lM) [50]. With normal enzymes this allows for sensi-
tive detection of drug-stimulated ATPase activity [51], but in
the case of the Y397W and Y1040W mutants, where we have
demonstrated a signiﬁcantly higher Km, this concentration is
now 1000 times lower than the Km, and thus 8-azido-nucleo-
tide trapping becomes almost insigniﬁcant. Perhaps trapping
similar to the WT enzyme could be obtained if a higher con-
centration of 8-azido-ATP was used in the assay with these
two enzymes. The increase in Km could also explain the impor-
tant eﬀect of these mutations on transport activity as measured
in yeast, since the cellular concentration of ATP in these
organisms is around 5 mM (a concentration about 10 timesand Y1263W variants in presence of various drugs. ATPase activities
ast three experiments ± S.D. Verapamil (VER), valinomycin (VAL),
romide (TPP+) were added at concentrations of 100, 100, 100, 50, 30,
Fig. 5. ATP hydrolysis by puriﬁed reconstituted Y397W and Y1040W mutants as a function of ATP concentration. The speciﬁc activity of puriﬁed
reconstituted WT Abcb1a and Y397W and Y1040W variants was measured as a function of MgATP concentration in the absence or presence of
100 lM verapamil (VER), 100 lM valinomycin (VAL), or 30 lM FK506. The points represent the mean of three or four independent experiments
and the error bars represent S.D. The curves are non-linear least-squares regression ﬁts of the mean data points to the Michaelis–Menten equation
which also provided the apparent Km(ATP) values.
306 I. Carrier et al. / FEBS Letters 581 (2007) 301–308the normal Km for the WT enzyme), which means that the mu-
tant enzymes Y397W and Y1040W would then be functioning
at sub-saturating concentrations of nucleotide.4. Conclusions
In this study, we wanted to determine which amino acid
side chains are in the vicinity of the adenine moiety of bound
nucleotide under binding and hydrolysis conditions. We thus
wanted to determine whether in Abcb1a an aromatic residue
was also responsible for binding the adenine moiety of bound
nucleotide as in HisP, ABCB1, MRP1, and HlyB. We also
hypothesized that if the tryptophan substitution at these posi-
tions was tolerated, these residues could be used in a trypto-
phan-free enzyme to monitor nucleotide occupancy of theNBDs during the catalytic cycle, as was done for F1-ATPase,
or dimer formation, as was done in MJ0796-E171Q. Two
homologous pairs of tyrosine residues were investigated. The
ﬁrst pair is Y397 in NBD1 and its homolog in NBD2:
Y1040, which are part of a conserved motif, the A-loop. The
second pair is Y618 and its homolog in NBD2: Y1263, which
are in the C-terminal portion of the NBD. In conclusion,
although photolabeling experiments suggested that Y618 and
Y1263, in NBD1 and NBD2, respectively, may be near the
azido group of 8-azidoATP during nucleotide binding in the
absence of vanadate, these residues do not seem to play a
major role in nucleotide binding during catalysis, as the activity
of the enzyme was not aﬀected by their substitution to trypto-
phan. Mutagenesis to replace these residues by less conserva-
tive amino acids, singly or in combination, could determine
whether they do actually have a role in catalysis. On the other
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Fig. 6. Photo-labeling of puriﬁed reconstituted Y397W, Y618W, Y1040W and Y1263W variants with Mg-8-azido-[a-32P]ATP. (A) Three
micrograms of puriﬁed reconstituted WT and mutant Abcb1a variants were UV-irradiated on ice in the presence of 3mM MgCl2 and 5, 10, 20, 40,
and 80 lM 8-azido-[a-32P]ATP. Photo-labeled samples were separated on 7.5% SDS–polyacrylamide gels and stained with Coomassie Blue followed
by autoradiography. The position of the molecular mass markers is given on the left. Experiment was carried out in duplicate. (B) Puriﬁed activated
WT and mutant Abcb1a variants were pre-incubated with 5 lM 8-azido-[a-32P]ATP and 3 mM MgCl2 for 20 min at 37 C with or without 200 lM
vanadate. Verapamil (100 lM) or FK506 (50 lM) was included as indicated above the lanes. Unbound ligands were removed by ultracentrifugation
and washing, and the samples were then UV irradiated. Photolabeled samples were then analyzed as described in (A).
I. Carrier et al. / FEBS Letters 581 (2007) 301–308 307hand, this suggests that the Y618W and Y1263W mutants may
turn out to be good probes for nucleotide occupancy, or per-
haps dimer formation, during the catalytic cycle, in tryptophan
ﬂuorescence assays, if their ﬂuorescence becomes altered by the
presence of nucleotide – or upon dimer formation; this will
need to be tested in the future, following introduction in the
tryptophan-less enzyme [52]. Finally, the residues of the A-
loop, Y397 and Y1040, in NBD1 and NBD2, respectively,
seem to play an important role in ATP hydrolysis by Abcb1a
by contributing signiﬁcantly to the positioning and maintain-
ing of the nucleotide in the active site. Our results are thus
in agreement with those obtained by Kim et al. [2] and Zhao
et al. [37] with the eukaryotic enzymes ABCB1 and MRP1,
respectively. A major diﬀerence, though, is that in our
eukaryotic enzyme, a simple substitution to a conserved amino
acid produces a signiﬁcant change in the catalytic properties of
the enzyme, whereas these eﬀects are only observed in ABCB1
and MRP1 when non-conserved substitutions are introduced
in each NBD (ABCB1 and MRP1) or when the conserved
substitutions are introduced simultaneously in both NBDs
(W in ABCB1) [2,37]. Perhaps the mouse enzyme is less
tolerant of substitutions at this position because the NBD is
more rigid and/or because there are no (or not as many) other
residues which contribute to the stabilization of ATP binding
via the adenine moiety, as may be the case in ABCB1 or
MRP1.
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